These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38691069)

  • 1. Bruton's Tyrosine Kinase Inhibition in Pemphigus: An Embattled Frontier.
    Payne AS; Manfredo Vieira S
    J Invest Dermatol; 2024 Aug; 144(8):1667-1670. PubMed ID: 38691069
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
    Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Marcotte D; McDowell B; Mertsching E; Negrou E; Otipoby KL; Poreci U; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M
    Bioorg Med Chem; 2019 Jul; 27(13):2905-2913. PubMed ID: 31138459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.
    Carnero Contentti E; Correale J
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):377-381. PubMed ID: 32910702
    [No Abstract]   [Full Text] [Related]  

  • 5. Navigating a paradigm shift: Bruton's tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy.
    Rao AG
    Int Immunopharmacol; 2024 Jun; 135():112265. PubMed ID: 38781611
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting Bruton's tyrosine kinase in B cell malignancies.
    Hendriks RW; Yuvaraj S; Kil LP
    Nat Rev Cancer; 2014 Apr; 14(4):219-32. PubMed ID: 24658273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
    Axelrod M; Ou Z; Brett LK; Zhang L; Lopez ER; Tamayo AT; Gordon V; Ford RJ; Williams ME; Pham LV; Weber MJ; Wang ML
    Leukemia; 2014 Feb; 28(2):407-10. PubMed ID: 23979520
    [No Abstract]   [Full Text] [Related]  

  • 8. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
    Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
    J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
    Furman RR; Luan Y; Bilotti E; Graef T
    Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
    Liu L; Shi B; Wang X; Xiang H
    Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
    Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
    J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
    Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
    Wiestner A
    J Clin Oncol; 2013 Jan; 31(1):128-30. PubMed ID: 23045586
    [No Abstract]   [Full Text] [Related]  

  • 14. A fresh look at covalent BTK inhibitor resistance.
    Roeker LE
    Blood; 2024 Sep; 144(10):1029-1031. PubMed ID: 39235796
    [No Abstract]   [Full Text] [Related]  

  • 15. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
    Liu N; Hoogendoorn S; van de Kar B; Kaptein A; Barf T; Driessen C; Filippov DV; van der Marel GA; van der Stelt M; Overkleeft HS
    Org Biomol Chem; 2015 May; 13(18):5147-57. PubMed ID: 25849561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
    Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
    Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
    Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
    Davids MS; Brown JR
    Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.